Your Trusted Brand for Over 35 Years

Chemotherapy References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Hsueh CKDPSGK. Selective inhibition of cyclooxygenase-2 (COX-2) enhances chemotherapy-induced apoptosis (meeting abstract). Proc Annu Meet Am Soc Clin Oncol. 1999;(18):A606.
  2. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res. 2001 Oct;7(10):2998-3005.
  3. Swamy MV, Cooma I, Reddy BS, et al. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol. 2002 Apr;20(4):753-9.
  4. Ura H, Obara T, Nishino N, et al. Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res. 1994 Jun;85(6):633-8.
  5. Narisawa T, Morotomi M, Fukaura Y, et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res. 1996 Aug;87(8):798-804.
  6. Tatsuta M, Iishi H, Baba M, et al. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer. 1998 Feb;77(4):581-7.
  7. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology. 2000 Sep;59(3):245-54.
  8. Furst J, Haller T, Chwatal S, et al. Simvastatin inhibits malignant transformation following expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Cell Physiol Biochem. 2002;12(1):19-30.
  9. van de Donk NW, Kamphuis MM, Lokhorst HM, et al. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia. 2002 Jul;16(7):1362-71.
  10. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001 Apr 6;84(7):886-91.
  11. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000 Jun 24;355(9222):2218-9.
  12. Edwards CJ, Russell RG, Spector TD. Statins and bone: myth or reality? Calcif Tissue Int. 2001 Aug;69(2):63-6.
  13. Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002 Mar 11;162(5):537-40.
  14. Waltregny D, Bellahcene A, de L, X, et al. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res. 2000 May;15(5):834-43.
  15. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2002;(1):CD003474.
  16. Papapoulos SE, Hamdy NA, van der PG. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer. 2000 Jun 15;88(12 Suppl):3047-53.
  17. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer. 2000 Mar;36(4):476-82.
  18. Berruti A, Dogliotti L, Tucci M, et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol. 2001 Dec;166(6):2023-31.
  19. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. 2001 Jun 15;91(12):2238-45.
  20. Reyes-Moreno C, Sourla A, Choki I, et al. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology. 1998 Aug;52(2):341-7.
  21. Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 1;19(11):2856-64.
  22. Paule B. [Interleukin-6 and bone metastasis of renal cancer: molecular bases and therapeutic implications]. Prog Urol. 2001 Apr;11(2):368-75.
  23. Garcia-Moreno C, Mendez-Davila C, de La PC, et al. Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate. 2002 Mar 1;50(4):241-6.
  24. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology. 1999 Oct;117(4):838-47.
  25. Tajima M. [Chronic cardiotoxicity of anthracycline derivatives and possible prevention by coenzyme Q10]. Gan No Rinsho. 1984 Jul;30(9 Suppl):1211-6.
  26. Mortensen SA, Aabo K, Jonsson T, et al. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection. Int J Clin Pharmacol Res. 1986;6(2):137-50.
  27. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15 Suppl:s207-s212.
  28. De Flora S, D'Agostini F, Masiello L, et al. Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int J Cancer. 1996 Sep 17;67(6):842-8.
  29. D'Agostini F, Bagnasco M, Giunciuglio D, et al. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol. 1998 Aug;13(2):217-24.
  30. Schmidinger M, Budinsky AC, Wenzel C, et al. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr. 2000 Jul 28;112(14):617-23.
  31. Agha AM, El Fattah AA, Al Zuhair HH, et al. Chemopreventive effect of Ginkgo biloba extract against benzo(a)pyrene-induced forestomach carcinogenesis in mice: amelioration of doxorubicin cardiotoxicity. J Exp Clin Cancer Res. 2001 Mar;20(1):39-50.
  32. Prasad KN, Cole WC, Kumar B, et al. Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr. 2001 Oct;20(5 Suppl):450S-63S.
  33. Blasiak J, Gloc E, Wozniak K, et al. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem Biol Interact. 2002 Apr 20;140(1):1-18.
  34. Somasundaram S, Edmund NA, Moore DT, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002 Jul 1;62(13):3868-75.
  35. Holland JFFEIBRCJrPREWRR. Holland-Frei Cancer Medicine.2000 5th edition.
  36. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000 Apr;105(8):1045-7.
  37. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000 Apr;105(8):R15-R24.
  38. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 2001 Sep;7(5):427-36.
  39. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002 May 15;62(10):2731-5.
  40. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7 Suppl 4:31-9.
  41. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54.
  42. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate. 2001 Feb 1;46(2):98-107.
  43. Hurley MM, Marcello K, Abreu C, et al. Signal transduction by basic fibroblast growth factor in rat osteoblastic Py1a cells. J Bone Miner Res. 1996 Sep;11(9):1256-63.
  44. Mukhopadhyay D, Tsiokas L, Zhou XM, et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995 Jun 15;375(6532):577-81.
  45. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998 Jun;4(6):376-83.
  46. Seol DW, Chen Q, Zarnegar R. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene. 2000 Feb 24;19(9):1132-7.
  47. Zhang F, Altorki NK, Mestre JR, et al. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis. 1999 Mar;20(3):445-51.
  48. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999 Oct 28;18(44):6013-20.
  49. Jee SH, Shen SC, Tseng CR, et al. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol. 1998 Oct;111(4):656-61.
  50. Jung YD, Kim MS, Shin BA, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer. 2001b Mar 23;84(6):844-50.
  51. Navis I, Sriganth P, Premalatha B. Dietary curcumin with cisplatin administration modulates tumour marker indices in experimental fibrosarcoma. Pharmacol Res. 1999 Mar;39(3):175-9.
  52. Michaels SBDM. In Vivo Assessment of NF-kB Inhibitors as Chemosensitizers: Study 4967. Paper presented at the Annual Meeting of the American Association for Cancer Research, New Orleans, March 24-28, 2001.2001;March 24-28, 2001 Study 4967.
  53. Wagdi P, Fluri M, Aeschbacher B, et al. Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. A pilot study. Jpn Heart J. 1996 May;37(3):353-9.
  54. Chinery R, Brockman JA, Peeler MO, et al. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med. 1997 Nov;3(11):1233-41.
  55. You H, Yu W, Sanders BG, et al. RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ. 2001 Sep;12(9):471-80.
  56. Faure H, Coudray C, Mousseau M, et al. 5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycin-treated patients. Free Radic Biol Med. 1996;20(7):979-83.
  57. Guo L, Bai SP, Zhao L, Wang XH. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol. 2011 Sep 18.
  58. Liu L, Zhang J, He R, Zhou L, Zhang J. [Astragalus injection ameliorates cisplatin-induced nephrotoxicity in mice]. Zhongguo Zhong Yao Za Zhi. 2010 Oct;35(20):2736-40
  59. Duan P, Wang ZM. [Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Jul;22(7):515-7. Chinese.
  60. Choi EH, Ok HE, Yoon Y, Magnuson BA, Kim MK, Chun HS. Protective effect of anthocyanin-rich extract from bilberry (Vaccinium myrtillus L.) against myelotoxicity induced by 5-fluorouracil. Biofactors. 2007;29(1):55-65.
  61. Choi EH, Park JH, Kim MK, Chun HS. Alleviation of doxorubicin-induced toxicities by anthocyanin-rich bilberry (Vaccinium myrtillus L.) extract in rats and mice. Biofactors. 2010 Jul-Aug;36(4):319-27.
  62. Ashour OM, Elberry AA, Alahdal A, Al Mohamadi AM, Nagy AA, Abdel-Naim AB, Abdel-Sattar EA, Mohamadin AM. Protective effect of bilberry (Vaccinium myrtillus) against doxorubicin-induced oxidative cardiotoxicity in rats. Med Sci Monit. 2011 Apr;17(4):BR110-5.
  63. Vanella A, Campisi A, di Giacomo C, et al. Enhanced resistance of adriamycin-treated MCR-5 lung fibroblasts by increased intracellular glutathione peroxidase and extracellular antioxidants. Biochem Mol Med. 1997 Oct;62(1):36-41.
  64. Yeo JK, Cha SD, Cho CH, et al. Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. Cancer Lett. 2002 Aug 8;182(1):83-92.
  65. Sinha R, Kiley SC, Lu JX, et al. Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett. 1999 Nov 15;146(2):135-45.
  66. Sinha R, Medina D. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis. 1997 Aug;18(8):1541-7.
  67. Jung U, Zheng X, Yoon SO, et al. Se-methylselenocysteine induces apoptosis mediated by reactive oxygen species in HL-60 cells. Free Radic Biol Med. 2001a Aug 15;31(4):479-89.
  68. Ip C, Dong Y. Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res. 2001 Mar;21(2A):863-7.
  69. Kennedy RS, Konok GP, Bounous G, et al. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study. Anticancer Res. 1995 Nov;15(6B):2643-9.
  70. Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000 Nov;20(6C):4785-92.
  71. Tsai WY, Chang WH, Chen CH, et al. Enchancing effect of patented whey protein isolate (Immunocal) on cytotoxicity of an anticancer drug. Nutr Cancer. 2000;38(2):200-8.
  72. Pugliese PT, Jordan K, Cederberg H, et al. Some biological actions of alkylglycerols from shark liver oil. J Altern Complement Med. 1998;4(1):87-99.
  73. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999 Nov;35(12):1688-92.
  74. Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997a Aug;23(1):15-9.
  75. Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997b Mar;5(2):126-9.
  76. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer. 2002 Mar;10(2):110-6.
  77. Maestroni GJ, Covacci V, Conti A. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res. 1994a May 1;54(9):2429-32.
  78. Maestroni GJ, Conti A, Lissoni P. Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res. 1994b Sep 1;54(17):4740-3.
  79. Maestroni GJ. kappa-Opioid receptors in marrow stroma mediate the hematopoietic effects of melatonin-induced opioid cytokines. Ann N Y Acad Sci. 1998 May 1;840:411-9.
  80. Conti A, Maestroni GJ. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res. 1995 Oct;19(3):103-10.
  81. Lissoni PAABSTGMMP. Immunotherapy with subcutaneous low-dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer. Oncol Rep. 1996;3(5):947-9.
  82. Koda K, Miyazaki M et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.Int J Oncol . 2003;23(1):165-72.
  83. Noguchi K, Tanimura H et al. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.Anticancer Res . 1995;15(2):255-8.
  84. Yokoe T, Iino Y et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.Anticancer Res . 1997;17(4A):2815-8.
  85. Shibata M, Shimura T, Nishina Y et al. [PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer]. Gan To Kagaku Ryoho. 2011 May;38(5):797-801.
  86. Matsuda M, Matsusaka S, Kuboki Y et al. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer]. [Article in Japanese] Gan To Kagaku Ryoho. 2008 Mar;35(3):461-6.
  87. Kobrinsky NL, Sjolander DE, Cheang MS, et al. Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer. J Clin Oncol. 1999 Nov;17(11):3426-30.
  88. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, et al. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer. 1997 Jul;33(8):1202-8.
  89. Murray LS, Jodrell DI, Morrison JG, et al. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol ). 1998;10(1):35-8.
  90. Matsumoto S, Imaeda Y, Umemoto S, et al. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer. 2002 Jan 21;86(2):161-7.
  91. Keating A, Chez RA. Ginger syrup as an antiemetic in early pregnancy. Altern Ther Health Med. 2002 Sep;8(5):89-91.
  92. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003 Nov 15;21(22):4105-11.
  93. Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003a May;39(8):1074-80.
  94. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003 Jun 15;97(12):3090-8.
  95. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003b Nov 15;21(22):4112-9.
  96. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003 May 1;97(9):2290-300.
  97. EMDND® (aprepitant) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of MERCK & Co., INC; 2003.
  98. Tsai WS, Nagawa H, Muto T. Differential effects of polyunsaturated fatty acids on chemosensitivity of NIH3T3 cells and its transformants. Int J Cancer. 1997 Jan 27;70(3):357-61.
  99. Ogilvie GK, Fettman MJ, Mallinckrodt CH, et al. Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. Cancer. 2000 Apr 15;88(8):1916-28.
  100. Lou YR, Lu YP, Xie JG, et al. Effects of oral administration of tea, decaffeinated tea, and caffeine on the formation and growth of tumors in high-risk SKH-1 mice previously treated with ultraviolet B light. Nutr Cancer. 1999;33(2):146-53.
  101. Blasina A, Price BD, Turenne GA, et al. Caffeine inhibits the checkpoint kinase ATM. Curr Biol. 1999 Oct 7;9(19):1135-8.
  102. Ribeiro JC, Barnetson AR, Jackson P, et al. Caffeine-increased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines. Int J Radiat Biol. 1999 Apr;75(4):481-92.
  103. Jiang X, Lim LY, Daly JW, et al. Structure-activity relationships for G2 checkpoint inhibition by caffeine analogs. Int J Oncol. 2000 May;16(5):971-8.
  104. Valenzuela MT, Mateos S, Ruiz de Almodovar JM, et al. Variation in sensitizing effect of caffeine in human tumour cell lines after gamma-irradiation. Radiother Oncol. 2000 Mar;54(3):261-71.
  105. Kang JH, Song KH, Woo JK, et al. Ginsenoside Rp1 from Panax ginseng exhibits anti-cancer activity by down-regulating of the IGF-1R/Akt pathway in breast cancer cells. Plant Foods Hum Nutr. 2011;66(3):298-305.
  106. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13(16):1859-76.
  107. Choi CH, Kang G, Min YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med. 2003 Mar;69(3):235-40.
  108. Matsunaga H, Katano M, Saita T, et al. Potentiation of cytotoxicity of mitomycin C by a polyacetylenic alcohol, panaxytriol. Cancer Chemother Pharmacol. 1994;33(4):291-7.
  109. Kikuchi Y, Sasa H, Kita T, et al. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs. 1991 Feb;2(1):63-7.
  110. Aherne SA, O'Brien NM. Protection by the flavonoids myricetin, quercetin, and rutin against hydrogen peroxide-induced DNA damage in Caco-2 and Hep G2 cells. Nutr Cancer. 1999;34(2):160-6.
  111. Yang JH, Hsia TC, Kuo HM, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos. 2006 Feb;34(2):296-304.
  112. Morrow DM, Fitzsimmons PE, Chopra M, et al. Dietary supplementation with the anti-tumour promoter quercetin: its effects on matrix metalloproteinase gene regulation. Mutat Res. 2001 Sep 1;480-481:269-76.
  113. Bach A, Bender-Sigel J, Schrenk D, Flugel D, Kietzmann T. The antioxidant quercetin inhibits cellular proliferation via HIF-1-dependent induction of p21WAF. Antioxid Redox Signal. 2010 Aug 15;13(4):437-48.
  114. Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol. 1994;34(6):459-64.
  115. Staedler D, Idrizi E, Kenzaoui BH, et al. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol. 2011 Nov;68(5):1161-72.
  116. Du G, Lin H, Wang M, et al. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother Pharmacol. 2010a Jan;65(2):277-87.
  117. Li SZ, Li K, Zhang JH, et al. The Effect of Quercetin On Doxorubicin Cytotoxicity in Human Breast Cancer Cells. Anticancer Agents Med Chem. 2012 Jun 18.
  118. Du G, Lin H, Yang Y, et al. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol. 2010b Jul;10(7):819-26.
  119. Hofmann J, Doppler W, Jakob A, et al. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer. 1988 Sep;42(3):382-8..
  120. Hofmann J, Fiebig HH, Winterhalter BR, et al. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer. 1990 Mar 15;45(3):536-9.
  121. Kaminski BM, Weigert A, Brüne B, et al. Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death. Cancer Chemother Pharmacol. 2011 May;67(5):1167-78.
  122. Sugiyama T, Sadzuka Y. Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. Cancer Lett. 1998 Nov 13;133(1):19-26.
  123. Sadzuka Y, Sugiyama T, Sonobe T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett. 2000a Apr 3;114(1-3):155-62.
  124. Sadzuka Y, Sugiyama T, Sonobe T. Improvement of idarubicin induced antitumor activity and bone marrow suppression by theanine, a component of tea. Cancer Lett. 2000b Oct 1;158(2):119-24.
  125. Sadzuka Y, Sugiyama T, Suzuki T, et al. Enhancement of the activity of doxorubicin by inhibition of glutamate transporter. Toxicol Lett. 2001 Sep 15;123(2-3):159-67.